Drug Profile
Research programme: protein-targeted therapeutics - Quorex/Biogen IDEC
Alternative Names: Protein-targeted therapeutics research programmeLatest Information Update: 23 Mar 2007
Price :
$50
*
At a glance
- Originator Biogen Idec; Quorex Pharmaceuticals
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Mar 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
- 05 Sep 2003 Preclinical trials in Cancer in USA (unspecified route)